Exact Sciences Corporation Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Exact Sciences CorporationHeadquarters: Madison, 
                        WI, United States
                    
Founded: 1995
Employees: 6,420
CEO: Mr. Kevin T. Conroy

                                    NASDAQ: EXAS
                                
                                            -3.06%
                                            
Market Cap$10.07 Billion

                        USD as of July 1, 2025
                    
                            Market Cap History

Exact Sciences Corporation Categories

United States Healthcare Diagnostics & Research
United States Healthcare United States Diagnostics & Research

Exact Sciences Corporation market capitalization over time

Evolution of Exact Sciences Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Exact Sciences Corporation

Top Competitors by Market Capitalization

Industry: Diagnostics & Research

Company	Market Cap (USD)
Thermo Fisher Scientific	$162.07 B
Danaher	$144.92 B
Siemens Healthineers AG	$64.17 B
Lonza Group Ltd	$49.67 B
IDEXX Laboratories, Inc.	$43.99 B

Sector:

Company	Market Cap (USD)
Lilly	$699.59 B
Johnson & Johnson	$374.29 B
AbbVie	$336.94 B
Novo Nordisk	$309.91 B
UnitedHealth Group	$279.90 B

Detailed Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Financials

Last Financial Reports Date	March 31, 2025
Revenue TTM	$2.83 B
EBITDA	$30.3 M
Gross Profit TTM	$1.97 B
Profit Margin	-36.06%
Operating Margin	-11.53%
Quarterly Revenue Growth	10.90%